Jazz Pharmaceuticals ((JAZZ)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jazz Pharmaceuticals is conducting a Phase I study titled ‘A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms.’ The study aims to evaluate the safety and tolerability of ONC206, an oral drug, in patients with recurrent CNS neoplasms, focusing on determining the maximum-tolerated dose and identifying dose-limiting toxicities.
The intervention being tested is ONC206, a drug belonging to the imipridone class of anti-cancer small molecules. It targets G protein-coupled receptors and is intended to treat various central nervous system tumors.
This interventional study follows a single-group assignment model with no masking, focusing primarily on treatment. The study is designed to assess the effects of ONC206 in a controlled, open-label setting.
The study began on September 1, 2020, with the latest update submitted on July 30, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
This update could influence Jazz Pharmaceuticals’ stock performance positively if the results show promising outcomes, as it would enhance their oncology portfolio. The involvement of the National Institutes of Health as a collaborator also adds credibility. Investors should monitor this study closely, considering the competitive landscape of CNS cancer treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.